0.27 USD
▼-0.00-0.15%
盘后 0.29 0.00%
2026-09-16
市值
$28.12M
市盈率
—
EPS
-0.08
股息率
—
52 周区间
0.24 – 0.45
成交量
406.83K
Beta
0.49
目标价
4.50
52W 低 0.2452W 高 0.45
价格走势
公司简介
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer’s disease in the United States and Colombia. The company’s lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer’s. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer’s disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare provi...